eflucimibe and Coronary-Artery-Disease

eflucimibe has been researched along with Coronary-Artery-Disease* in 1 studies

Reviews

1 review(s) available for eflucimibe and Coronary-Artery-Disease

Article	Year
Eflucimibe. Pierre Fabre/Eli Lilly. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3 Eflucimibe is an acyl coenzyme A:cholesterol acyltransferase inhibitor under development by Pierre Fabre SA and Eli Lilly & Co for the potential treatment of hypercholesterolemia and atherosclerosis. Phase II clinical trials commenced during 2002. Topics: Anilides; Animals; Anticholesteremic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Humans; Hypercholesterolemia; Sterol O-Acyltransferase	2003

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3

Eflucimibe is an acyl coenzyme A:cholesterol acyltransferase inhibitor under development by Pierre Fabre SA and Eli Lilly & Co for the potential treatment of hypercholesterolemia and atherosclerosis. Phase II clinical trials commenced during 2002.

Topics: Anilides; Animals; Anticholesteremic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Humans; Hypercholesterolemia; Sterol O-Acyltransferase

2003